Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 March 2018 Photo Johan Roux
Prof Heidi Hudson appointed as UFS Dean of the Faculty of the Humanities
Prof Heidi Hudson, Dean of the Faculty of the Humanities.

The Council of the University of the Free State (UFS) approved the appointment of Prof Heidi Hudson as Dean of the Faculty of the Humanities during a meeting on the Bloemfontein Campus on 22 January 2018. She assumed office on 1 March 2018.

Prof Hudson is a Professor of International Relations with a PhD in Strategic Studies, and has been recognised for her undisputed international standing, which resulted in the awarding of a B2 rating by the National Research Foundation, effective from 1 January 2018. She was co-editor of The International Feminist Journal of Politics for the past six and a half years, as well as a Global Fellow of the Peace Research Institute in Oslo (2014-2016). Prof Hudson currently serves on the Advisory Board of the African Peacebuilding Network at the Social Science Research Council in New York. In 2018, she will also be the Claude Ake Visiting Chair, hosted by the Department of Peace and Conflict Research, Uppsala University and the Nordic Africa Institute. Her Claude Ake Memorial Lecture will focus on the decolonisation of gender and peacebuilding in Africa. 

“Prof Hudson is a well-respected researcher and senior manager and will add immense value to the faculty. She has been associated with the UFS for almost 25 years and the institutional memory she brings to the position is indispensable. I look forward to working with her and to support her in realising her vision for the faculty,” says Prof Francis Petersen, UFS Rector and Vice-Chancellor. 
 
Prof Hudson started her academic career at the UFS, spent six years at the former University of Durban-Westville (1991-1996), after which she re-joined the Department of Political Science at the UFS, where she was Departmental Chairperson from 2006 to 2007. In 2009, she joined the Centre for Africa Studies as Africa Studies programme director (2009-2011), and has been the Director of the centre since September 2012. The centre was recently externally evaluated and the positive report testifies to her leadership. Prof Hudson managed to increase the centre’s international footprint in a short space of time and effected an increase in research outputs, as well as PhD enrolment and output.   
 
In addition to serving on the Faculty Committee of the Humanities, she is a long-standing member of the Faculty Research Committee and also chaired the Portfolio Committee on Quality Assurance (2005-2008), while also serving on the UFS Quality Assurance Committee (until 2008). She was Senate representative on the Institutional Forum (August 2013–July 2017) and a member of the UFS Gender Committee (until 2006). She was recently nominated to serve on the Senate Research Committee.
 
Prof Hudson has been acting in the position of Dean: Faculty of the Humanities since 1 October 2017. Her vision for the faculty includes, among others, curriculum renewal, interdisciplinary research, and improved governance at middle-management level.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept